Loading...
XNASXTLB
Market cap16mUSD
Dec 24, Last price  
1.88USD
1D
6.82%
1Q
-27.41%
Jan 2017
-40.75%
Name

X T L Biopharmaceuticals Ltd

Chart & Performance

D1W1MN
XNAS:XTLB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
154.12%
Rev. gr., 5y
%
Revenues
0k
P
3,454,0003,197,000454,000907,0005,940,000000938,0002,369,00041,000-6,00023,00029,00052,00069,00028,0001,466,000-459,0000
Net income
-2m
L-22.82%
-16,473,000-14,015,000-15,132,000-24,939,000-9,246,0002,587,000-1,257,000-1,207,000-1,390,000-2,476,000-2,527,000-4,311,000-2,545,000-781,0002,986,000-1,278,000-616,0001,901,000-2,309,000-1,782,000
CFO
-707k
L-21.53%
-14,495,000-10,466,000-12,587,000-21,457,000-10,578,000-2,488,000-735,000-1,801,000-1,506,000-2,499,000-2,470,000-1,861,000-1,732,000-1,125,000-816,000-908,000-850,000-1,049,000-901,000-707,000

Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
URL
https://www.xtlbio.com/
IPO date
Sep 01, 2000
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT